Huabao International Holdings Limited Overview
Huabao International is a China-centred "taste and scent" platform. It has historically been best known as one of China's leading suppliers of tobacco flavours and reconstituted tobacco leaf (RTL). Since 2020 the group has diversified into food flavours, fragrances, food and health ingredients, aroma chemicals and B2B condiments. It describes this as a "concentric diversification" strategy centred on the taste industry. The group reports four segments: Huabao Technology (formerly F&F and Food Ingredients), Tobacco Raw Materials, Aroma Raw Materials and Condiment. It serves five downstream markets: food and beverage, daily-use chemicals, health, catering and tobacco. The balance sheet is very strong, with roughly RMB5.7bn of net cash and wealth-management products at 30 June 2026. However, reported earnings have been repeatedly hit by goodwill impairments totalling about RMB3.5bn over FY2020–FY2025. Management's equity story now rests on internationalisation (Indonesia RTL, global tobacco majors), innovative tobacco (HNB and oral nicotine), health ingredients and shareholder returns.
Company's own description (FY2025 annual results). The company says it pursues concentric diversification centred on the taste industry, under the philosophy of "green, delicious and healthy". Its stated focus is on high-growth sectors, namely innovative tobacco, health and daily-use chemicals. Its four segments serve food and beverage, daily-use chemicals, the health industry, catering and tobacco, which management describes as large, resilient end markets. In the 1H2026 announcement, management restated the Huabao Technology segment around three businesses: "taste", "nutrition and health", and "scent and care". It described the renaming as a move from "flavours and fragrances manufacturer" to "integrated solutions provider".
Business model. Huabao is overwhelmingly a B2B formulator and manufacturer.
Product sales dominate revenue: No subscription or licensing revenue is disclosed. Value is created through proprietary formulations (flavour and fragrance compounds), process know-how (RTL papermaking and slurry processes, capsule drop-forming) and customer-specific co-development, especially with tobacco customers.
Value-chain position: - In flavours and fragrances, Huabao sits mid-stream. It buys aroma chemicals and natural extracts, some of which it makes in-house through the Aroma Raw Materials segment. It sells compounded flavours to cigarette makers, food and beverage brands and daily-chemical brands.
-
In tobacco materials it supplies RTL and "new materials" (flavour capsules and, historically, filter rods) to cigarette and HNB manufacturers.
-
In condiments (Jiahao, Jiafu) it is closer to the end-user. It sells chicken bouillon, mustard/wasabi, sauces, soup bases and customised compound seasonings to catering operators via distributors and, increasingly, through direct key-account sales.
Customer types: - Chinese state tobacco industrial companies, historically the dominant profit pool.
-
International tobacco majors. The 1H2026 filing says Huabao Technology has entered the supply chains of the world's top three tobacco customers.
-
Multinational and domestic food brands. Mondelez, Nestlé, Bright Dairy, Dali, Dayao and Orion are named in filings.
-
New-style tea chains.
-
Daily-chemical brands and hotels, including Atour Hotel, Li Zi, Lan Ju, Yu Mei Jing and Libai.
-
Health and nutrition brands, including New Hope, Yum China, Nuotelande and WARMSANTA.
-
Chain and SME restaurants, industrial food factories and condiment distributors. Jiahao had more than 650 Tier-1 distributors at end-2023.
Revenue mix (FY2025). Huabao Technology (F&F and food ingredients) was 37.8%, Condiment 23.9%, Aroma Raw Materials 23.2% and Tobacco Raw Materials 15.2%. In 1H2026 the mix was 38.2%, 26.4%, 24.8% and 10.6% respectively.
Independent characterisation. Huabao is in transition. Until about 2021, it was effectively a high-margin, quasi-regulated supplier to China's tobacco monopoly. Group gross margin was 63.4% in FY2020 and the F&F segment margin was about 60%. That profit pool has eroded structurally. Domestic tobacco purchasing policies changed, traditional RTL is in oversupply, and capsule prices have fallen. The group gross margin fell to 40.8% by FY2025. Management has used its cash pile to buy into lower-margin but larger and faster-growing categories: condiments, food ingredients, health ingredients and fragrances. It is also building international tobacco capacity in Indonesia and Paraguay. The acquired businesses have produced the repeated goodwill write-downs, notably Jiahao (2020, 2025), Shanghai Yifang, Yancheng Chunzhu and Jiangxi Xianghai. The tobacco-legacy CGUs were also written down (RTL in 2021, 2022 and 2024; tobacco flavours in 2024). As a result, the business now looks more like a diversified mid-cap Chinese ingredients company with a large net cash position, and less like a tobacco-flavour franchise.
Strategy
Stated strategy (FY2025 AR and 1H2026). The core is "concentric diversification" centred on the taste industry, with "green, delicious and healthy" as the guiding philosophy. A new three-year strategic plan began in 2026. Management describes 2026 as both a pivotal year for that plan and the group's 30th anniversary, and says it is approaching the plan with a "starting from zero" mindset.
Seven management priorities for 2026 (FY2025 outlook):
-
Drive execution through clearly defined priority tasks.
-
Use procurement as the entry point for cost reduction.
-
Roll out AI across the whole workforce.
-
Maintain strict compliance and advance ESG.
-
Improve collaboration between subsidiaries and segments.
-
Pursue organic growth and M&A as twin engines.
-
Strengthen capital-markets communication and reward shareholders through sustained cash dividends and buybacks.
Medium-term financial targets / guidance. Not publicly disclosed. The company gives no numeric revenue, margin or EPS guidance. The 1H2026 outlook speaks of a "solid foundation for achieving full-year targets" without quantifying them.
Products & Services
Pricing models are not publicly disclosed for any line. All products are sold on a B2B contract or purchase-order basis unless noted.
Huabao Technology segment
| Product line / brand | Description & capabilities | Target customer | Latest disclosed development (year) |
|---|---|---|---|
| Tobacco flavours (taste) | Custom flavour formulations for cigarettes. HNB-specific flavours designed for stable, layered aroma release across heating temperatures. Oral-tobacco flavour systems. | Chinese tobacco industrial companies; international tobacco majors (filings state entry into the top three global tobacco companies' supply chains) | Mass delivery to overseas customers (2025); HNB-specific flavours (1H2026) |
| Food flavours — savoury (taste) | Meat-product and "wet and spicy" snack flavours; biscuit seasonings; savoury compound flavours. Tianjin lab focused on northern savoury tastes. | Snack, meat, biscuit manufacturers; supermarket private label | Multiple new biscuit flavours (2025) |
| Food flavours — sweet / heat-resistant (taste) | Microcapsule paste flavours with temperature resistance. Potato and ginger microcapsule powders for baking and puffed foods. Regional flavours such as pandan and coconut. | Bakery, puffed food, dairy, beverage makers | Pandan and coconut launches (2023) |
| Natural flavours (taste) | More than ten certified natural flavour products. Industry-first CQC Food Ingredients Natural Degree certificate. Developed with the "Shanghai Natural Food Center". | Multinational and domestic food brands; export markets | Natural certifications (2025–1H2026) |
| Compound flavour products (taste) | Sweet and savoury compound flavour systems; mid-to-high-end food ingredients; local speciality flavour series | Brand owners, supermarkets | Portfolio build-out (1H2026) |
| New-style tea beverage ingredients | Taiwanese-style dried plum, honey grapefruit juice, frozen grape juice, canned red beans. Halal-certified for overseas expansion. | Freshly-made tea chains | Entry into the segment (2025) |
| Fruit ingredients / popping boba (nutrition & health; Shanghai Yifang) | Natural fruit products, jams, fruit pieces. "IceFire Magic Ball" popping boba. Freeze-resistant boba for ice cream, liquid-filled high-oil boba, heat-resistant boba for bakery. Food-grade boba for nicotine pouches developed for an international tobacco company. | Mondelez, Orion, beverage, bakery and dessert makers; tobacco company (nicotine-pouch boba) | Nicotine-pouch boba validated, with commercial breakthrough expected in 2026 |
| Functional / nutritional ingredients (Better World Naturals; Shandong and Jiangxi Jiacui bases) | Calcium citrate, nano-calcium, functional emulsions, fish-oil nanoemulsion, nanocrystalline curcumin, vitamins, minerals, natural extracts. Delivered as one-stop application solutions. | Sports nutrition, dairy, beverage, functional food brands (New Hope, Yum China, Nuotelande, WARMSANTA) | Large-scale delivery of nano-calcium and fish-oil nanoemulsion (1H2026); Korean contracts (2026) |
| Natural meat extracts / peptide flavouring (Hunan Jiapin) | Small-molecule peptide flavouring; bone extracts, bone materials, animal and plant extracts | Food processors, condiment makers | Consolidated from Jun 2025 |
| Daily-use fragrances (scent and care; Amber (Xiamen)) | Fragrances for fabric care, personal care, perfume, cosmetics, home fragrance, household cleaning, incense and disinfection, pet care, oral care. Eucalyptol LTB; microencapsulated fragrances; functional "emotional" fragrances with soothing, refreshing and anti-fatigue claims based on brainwave and micro-expression research. | Domestic daily-chemical brands (Li Zi, Lan Ju, Yu Mei Jing, Libai); hotels (Atour); distributors in Africa, Vietnam and Thailand | Original-scent series launched (1H2026); AI-GCMS platform under test |
Tobacco Raw Materials segment
| Product line | Description & capabilities | Target customer | Latest disclosed development |
|---|---|---|---|
| Traditional RTL (papermaking process) | Reconstituted tobacco leaf used as an additive in conventional cigarettes. Guangdong Jinye is one of the few STMA-designated bases. | Chinese tobacco industry | Volumes declining because of procurement policy changes. The industry has about 180,000 t of annual capacity against weaker demand (FY2021 filing). |
| Innovative / HNB RTL | RTL tailored for heat-not-burn sticks, made by drying, slurry and granule techniques. The Indonesian base has three lines and about 3,000 t of capacity. | International tobacco majors; regional tobacco companies | Indonesian line running at full load from late 2Q2026; master supply agreement being renewed (1H2026) |
| Flavour capsules (tobacco new materials) | Breakable flavour capsules for cigarettes and HNB. AI optical sorting machine in use. | Tobacco customers in nearly 20 countries (Asia, South America, Middle East, Eastern Europe; Argentina added in 2026) | Paraguay capsule factory initiated (1H2026) |
| Food and probiotic capsules | Capsule technology redeployed to food and probiotic controlled-release uses. Patent covers gastrointestinal controlled-release probiotic capsules. | Food, beverage, probiotic makers | Patent granted (2023) |
| Filter rods (divested) | Hunan Jishou filter rods, including binary cooling filters for HNB | Domestic tobacco | Disposed of in 2025 |
Aroma Raw Materials segment
| Product | Description | Target customer | Notes |
|---|---|---|---|
| Ethyl maltol | Synthetic sweet aroma enhancer | Food, beverage, tobacco, daily-chemical | Volume growth in 1H2026 |
| Natural citral | Natural citrus aroma chemical | F&F houses | Volume growth in 1H2026 |
| Leaf alcohols | Green-note aroma chemicals | F&F houses | Volume growth in 1H2026 |
| Furanone | Caramel / fruity aroma chemical | Food flavours | Volume growth in 1H2026 |
| Natural lactones | Creamy and fruity notes | Food and dairy flavours | Volume growth in 1H2026 |
| Low-carbon alcohols, esters, acids, aldehydes (Yancheng Chunzhu) | Basic food-flavour chemicals, mainly exported to Europe, the US, Southeast Asia and Japan | Food and daily-chemical F&F houses, feed, pharma | Goodwill partially impaired (2023) |
| Furan-derived chemicals (Jiangxi Xianghai) | Fine chemicals; patent on chloroethane recovery in alpha-ethyl furan carbinol production. Design capacity 8,500 t. | F&F, chemicals | Goodwill fully impaired (2023) |
Condiment segment
| Product / service | Description | Target customer | Notes |
|---|---|---|---|
| Chicken bouillon (liquid), chicken powder, chicken essence (Jiahao) | Umami-enhancing core products with regional flavour variants | SME restaurants via distributors; chains | Core of the Jiahao franchise |
| Wasabi / mustard paste | Flavour-enhancing product | Restaurants (Japanese cuisine, seafood) | Core product |
| Concentrated fruit juices (cooking), functional soy sauce, gravy, sauces | Flavour enhancers | Restaurants | Patent on inhibiting browning in concentrated citrus juice (2023) |
| Commercial soup bases | Standardised soup bases for chains | Chain restaurants; retail soup-base business | One of three "core services" (2026) |
| Intelligent kitchen-robot sauces ("robot + sauce") | Sauces designed for kitchen robots, linked to an investment in a kitchen-robot company | Chains seeking automation | Growth reported in 1H2026 |
| Customised flexible compound seasonings | B2B custom compound seasonings | Chains, industrial factories | Growth reported in 1H2026 |
| Jiangsu Jiafu compound condiments and spices | Retail OEM, catering and industrial channels; overseas customisation; hot-pot bases | Chain caterers, industrial clients, overseas OEM | New factory construction began end-July 2026 |
Financial Narrative
Income statement
Notes:
-
FY2021 and FY2023 EBITDA are computed as operating profit plus segment depreciation and amortisation. FY2023 agrees with the RMB695.6m comparative in the FY2024 announcement.
-
FY2024 and FY2025 EBITDA are as reported.
-
FY2021–FY2023 adjusted EBITDA is derived from the company's disclosed "EBITDA margin" (excluding share-based compensation and goodwill impairment) of 43.5%, 32.2% and 22.9%. FY2024–FY2025 figures are the company's Non-HKFRS EBITDA.
-
FY2020 comparatives: revenue RMB3,854.1m; attributable profit RMB418.4m; DPS HK15.0c.
Margins and growth
Revenue CAGR FY2021–FY2025 was −2.7%. Over FY2020–FY2025 it was −2.0%.
Balance sheet
At 30 June 2026 the position was as follows:
-
Cash: RMB4,292.9m
-
Wealth-management products: RMB1,580.3m
-
Borrowings: RMB126.4m
-
Net cash including WMP: about RMB5,746.8m
-
Equity attributable: RMB11,293.3m
-
Total assets: RMB13,970.9m
Cash flow
Blank cells mean the figure was not available in the results announcements retrieved; it appears in the full annual reports. FY2023 and FY2025 announcements give only investing-activity totals: net cash used of RMB2,604.7m in FY2023 and RMB925.8m in FY2025, both dominated by WMP purchases. FY2022 net investing inflow was RMB1,244.0m. 1H2026 OCF was RMB93m, against RMB214m in 1H2025. Buybacks in 1H2026 totalled HK$24.1m for 6.286m shares.
Commentary on trends, inflections and drivers
Revenue. Revenue has been broadly flat to down in nominal terms for five years. It peaked at RMB3.88bn in FY2021 and bottomed at RMB3.31bn in FY2023. Composition has changed sharply.
-
F&F (tobacco flavours) revenue fell by RMB609m between FY2021 and FY2025. The FY2023 and FY2025 filings attribute this to changing demand from domestic tobacco customers and tougher competition.
-
Condiments, aroma chemicals and (from FY2025) international tobacco materials together added about RMB215m over the same period.
-
The 1H2026 rebound (+15.9%) is the strongest growth in more than five years. However, it is partly inorganic, coming from the consolidation of Jiangsu Jiafu (from August 2025) and Hunan Jiapin (from June 2025).
Gross margin. Gross margin fell 22.6 points from FY2020 (63.4%) to FY2025 (40.8%), and stayed at 40.8% in 1H2026. This is the single most important trend. It reflects mix dilution away from very high-margin tobacco flavours and traditional RTL, price competition in capsules and aroma chemicals, and inventory and PP&E impairments booked within cost of sales.
Operating line. The operating line is volatile because of goodwill impairments: RMB495.5m (FY2020), RMB293.3m (FY2021), RMB1,507.7m (FY2022), RMB56.5m (FY2023), RMB630.9m (FY2024) and RMB488.4m (FY2025), about RMB3.47bn in total. Excluding impairments and share-based compensation, the Non-HKFRS operating profit fell from about RMB1,408m in FY2021 (impairment-adjusted) to RMB223m in FY2025. This shows the underlying earnings decline is real and not only an accounting effect.
Cost structure. Several cost lines have moved materially:
Administrative expenses: rose from 21.7% of revenue in FY2021 to 27.8% in FY2025. Share-based compensation rose to about RMB96m in FY2025, against RMB49m in FY2024.
Selling and marketing expenses: rose to 13.1% of revenue in FY2025 (from 7.5% in FY2021) as the group built overseas sales teams.
1H2026 operating leverage: Administrative expenses fell to 25.3% of revenue and selling expenses to 10.3%.
Below the line. Finance income (RMB98m in FY2025) and government grants (RMB90m) are meaningful supports to profit. Both fell in 1H2026: finance income was RMB25m and grants RMB11m. This is why attributable profit fell 11.7% in 1H2026 despite higher operating profit.
Balance sheet. The balance sheet is exceptionally liquid. Cash plus WMP has been RMB6.2–6.8bn at every year-end since FY2021. Gross debt has fallen from RMB2.71bn (FY2020) to RMB0.13bn (June 2026), and all of it is short-term RMB borrowing. Intangible assets have almost halved (RMB6,226m in FY2020 to RMB3,148.6m in FY2025) as goodwill was written down. This lowers the risk of future impairments, but RMB3.1bn of intangibles remain, much of it related to Jiahao.
Working capital. Working capital efficiency has improved. The cash conversion cycle shortened from 243 days (FY2023) to 190 days (FY2025), and inventory days fell to 142 in 1H2026. Operating cash flow conversion has been strong relative to reported losses: FY2025 OCF of RMB826m compares with Non-HKFRS profit of RMB179m.
Shareholder returns. The group has paid dividends, mostly special dividends, in every year including loss years. FY2025 total DPS was HK9.9c, and dividends paid totalled RMB277.5m.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Huabao Technology / F&F & Food ingredients (CNY Mn) | 1,926.7 | 1,877.3 | 1,464.4 | 1,339.0 | 1,317.5 |
Tobacco raw materials (CNY Mn) | 565.4 | 454.3 | 464.7 | 467.7 | 528.8 |
Aroma raw materials (CNY Mn) | 714.0 | 924.3 | 624.7 | 791.5 | 807.0 |
Condiment (CNY Mn) | 676.5 | 573.1 | 754.1 | 774.6 | 831.2 |
Others (CNY Mn) | 0.0 | 0.0 | 0.0 | 0.5 | 0.1 |
Group revenue (CNY Mn) | 3,882.7 | 3,829.0 | 3,307.8 | 3,373.3 | 3,484.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment — Huabao Technology / F&F
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Huabao Technology / F&F (CNY Mn) | 1,104.1 | 824.1 | 405.5 | -300.5 | 55.4 |
Tobacco raw materials (CNY Mn) | -80.1 | -237.5 | 90.8 | -82.1 | 22.8 |
Aroma raw materials (CNY Mn) | 59.1 | 79.5 | -83.4 | 22.8 | 78.9 |
Condiment (CNY Mn) | 136.9 | -1,116.9 | 116.8 | 97.6 | -409.1 |
Unallocated / others (CNY Mn) | -105.5 | -157.1 | -151.6 | -139.7 | -108.8 |
Group operating profit (CNY Mn) | 1,114.5 | -608.0 | 378.1 | -401.9 | -360.9 |
Segment Margins & Growth (%)
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Huabao Technology / F&F margin (%) | 57.3 | 43.9 | 27.7 | -22.4 | 4.2 |
Tobacco raw materials margin (%) | -14.2 | -52.3 | 19.5 | -17.6 | 4.3 |
Aroma raw materials margin (%) | 8.3 | 8.6 | -13.4 | 2.9 | 9.8 |
Condiment margin (%) | 20.2 | -194.9 | 15.5 | 12.6 | -49.2 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Huabao Technology / F&F YoY growth (%) | -7.6 | -2.6 | -22.0 | -8.6 | -1.6 |
Tobacco raw materials YoY growth (%) | -9.0 | -19.7 | 2.3 | 0.7 | 13.1 |
Aroma raw materials YoY growth (%) | 11.8 | 29.5 | -32.4 | 26.7 | 2.0 |
Condiment YoY growth (%) | 34.6 | -15.3 | 31.6 | 2.7 | 7.3 |
Huabao Technology / F&F share of revenue (%) | 49.6 | 49.0 | 44.3 | 39.7 | 37.8 |
Tobacco raw materials share of revenue (%) | 14.6 | 11.9 | 14.0 | 13.9 | 15.2 |
Aroma raw materials share of revenue (%) | 18.4 | 24.1 | 18.9 | 23.5 | 23.2 |
Condiment share of revenue (%) | 17.4 | 15.0 | 22.8 | 23.0 | 23.9 |
Segment Revenue
| Segment | 1H2025 revenue | 1H2026 revenue | YoY % | 1H2025 result | 1H2026 result |
|---|---|---|---|---|---|
Huabao Technology | 595.7 | 717.3 | 20.4 | 18.8 | 105.8 |
Tobacco raw materials | 238.4 | 199.3 | -16.4 | 31.3 | 4.2 |
Aroma raw materials | 405.4 | 465.6 | 14.9 | 61.7 | 38.0 |
Condiment | 381.6 | 495.8 | 29.9 | 38.9 | 47.7 |
Others/unallocated | 0.0 | 0.1 | — | -28.6 | -52.2 |
Group | 1,621.2 | 1,878.1 | 15.9 | 122.2 | 143.4 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 3,882.7 | 3,829.0 | 3,307.8 | 3,373.3 | 3,484.7 |
Gross profit (CNY Mn) | 2,296.7 | 1,877.6 | 1,469.4 | 1,441.4 | 1,423.1 |
Goodwill impairment (CNY Mn) | 293.3 | 1,507.7 | 56.5 | 630.9 | 488.4 |
Operating profit (CNY Mn) | 1,114.5 | -608.0 | 378.1 | -401.9 | -360.9 |
EBITDA, operating profit + D&A (CNY Mn) | 1,391.6 | -277.7 | 695.6 | -69.7 | -8.4 |
Adjusted EBITDA, company non-GAAP (CNY Mn) | 1,689.0 | 1,233.0 | 757.5 | 624.1 | 575.7 |
Profit before tax (CNY Mn) | 1,147.4 | -720.2 | 415.9 | -402.4 | -286.8 |
Profit for the year incl. NCI (CNY Mn) | 895.8 | -901.1 | 290.5 | -458.9 | -405.5 |
Net profit attributable to shareholders (CNY Mn) | 675.1 | -1,054.5 | 233.6 | -385.5 | -388.8 |
Basic EPS (MYR Bn cents) | 21.70 | -32.65 | 7.23 | -11.94 | -12.04 |
Diluted EPS (MYR Bn cents) | 21.70 | -32.65 | 7.23 | -11.94 | -12.04 |
Total DPS for the year (HK cents) | 8.40 | 8.48 | 8.50 | 8.50 | 9.90 |
R&D expense (CNY Mn) | 250.8 | 266.2 | 253.2 | 245.2 | 287.0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 59.2 | 49.0 | 44.4 | 42.7 | 40.8 |
Operating margin (%) | 28.7 | -15.9 | 11.4 | -11.9 | -10.4 |
EBITDA margin, reported basis (%) | 35.8 | -7.3 | 21.0 | -2.1 | -0.2 |
Adjusted EBITDA margin (%) | 43.5 | 32.2 | 22.9 | 18.5 | 16.5 |
Net margin, attributable (%) | 17.4 | -27.5 | 7.1 | -11.4 | -11.2 |
Revenue growth YoY (%) | 0.7 | -1.4 | -13.6 | 2.0 | 3.3 |
R&D as % of revenue (%) | 6.5 | 7.0 | 7.7 | 7.3 | 8.2 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 18,025.1 | 16,619.0 | 16,002.1 | 15,002.1 | 14,390.3 |
Cash and bank balances (CNY Mn) | 3,553.4 | 4,748.0 | 2,539.5 | 5,562.2 | 3,601.3 |
Bank wealth-management products at FVPL (CNY Mn) | 3,256.5 | 1,594.3 | 3,847.7 | 649.5 | 2,646.8 |
Short-term borrowings (CNY Mn) | 962.8 | 677.7 | 419.3 | 194.0 | 146.9 |
Long-term borrowings (CNY Mn) | 0.0 | 0.0 | 36.0 | 0.0 | 0.0 |
Total debt (CNY Mn) | 962.8 | 677.7 | 455.3 | 194.0 | 146.9 |
Net debt, debt minus cash excl. WMP (CNY Mn) | -2,590.6 | -4,070.3 | -2,084.2 | -5,368.2 | -3,454.4 |
Net debt incl. WMP (CNY Mn) | -5,847.1 | -5,664.6 | -5,931.9 | -6,017.7 | -6,101.2 |
Equity attributable to shareholders (CNY Mn) | 13,884.7 | 12,650.9 | 12,480.4 | 12,078.5 | 11,378.6 |
Total equity incl. NCI (CNY Mn) | 15,718.8 | 14,557.4 | 14,271.1 | 13,720.4 | 13,036.3 |
Intangible assets incl. goodwill (CNY Mn) | 5,847.3 | 4,322.7 | 4,188.0 | 3,462.2 | 3,148.6 |
Inventories (CNY Mn) | 897.2 | 1,020.0 | 994.6 | 893.3 | 894.8 |
Current assets (CNY Mn) | 8,872.8 | 8,699.1 | 8,358.0 | 8,163.5 | 8,148.6 |
Current liabilities (CNY Mn) | 2,133.9 | 1,754.9 | 1,382.5 | 1,129.0 | 1,202.6 |
Working capital / net current assets (CNY Mn) | 6,738.9 | 6,944.1 | 6,975.4 | 7,034.5 | 6,946.0 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 1,413.2 | — | — | 679.7 | 825.9 |
Capex, PP&E and intangibles (CNY Mn) | 412.6 | — | — | — | — |
Free cash flow, OCF minus capex (CNY Mn) | 1,000.6 | — | — | — | — |
Dividends paid to shareholders (CNY Mn) | 394.7 | — | 252.3 | — | 277.5 |
Dividends paid to NCI (CNY Mn) | 206.1 | — | 184.0 | — | 42.4 |
Share buybacks (CNY Mn) | 0.0 | 0.0 | 0.0 | — | 0.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable NI ÷ average attributable equity (%) | 5.2 | -7.9 | 1.9 | -3.1 | -3.3 |
ROA, attributable NI ÷ average total assets (%) | 3.8 | -6.1 | 1.4 | -2.5 | -2.6 |
ROIC, analyst estimate, 25% notional tax, cash-adjusted capital (%) | 8.5 | -5.1 | 3.4 | -3.9 | -3.9 |
Current ratio (x) | 4.16 | 4.96 | 6.05 | 7.23 | 6.78 |
Debt / attributable equity, company definition (%) | 6.9 | 5.4 | 3.6 | 1.6 | 1.3 |
Net debt / adjusted EBITDA (x) | -1.53 | -3.30 | -2.75 | -8.60 | -6.00 |
Interest coverage, operating profit ÷ finance costs (x) | 13.7 | -16.0 | 15.2 | -19.1 | -17.2 |
Asset turnover, revenue ÷ average total assets (x) | 0.22 | 0.22 | 0.20 | 0.22 | 0.24 |
Trade receivable days (company-reported) | 87 | 89 | 97 | 81 | 83 |
Inventory days (company-reported) | 199 | 177 | 197 | 176 | 156 |
Trade payable days (company-reported) | 65 | 53 | 51 | 47 | 49 |
Cash conversion cycle (days) | 221 | 213 | 243 | 210 | 190 |
Geographic Revenue
| Segment | Domestic trend (FY2025–1H2026) | International trend (FY2025–1H2026) |
|---|---|---|
Huabao Technology | Tobacco flavours down; food flavours, tea and health up | Rapid overseas fragrance growth; Indonesia food complex due 2H2026; Korean health contracts |
Tobacco raw materials | Traditional RTL declining; filter rods divested | Capsules in about 20 countries; Indonesian RTL at full load; Paraguay plant initiated; Middle East disruption in 1H2026 |
Aroma raw materials | Price competition | Indonesia localisation; North America, SE Asia and Europe distributors |
Condiment | SME catering weak; key accounts growing | Jiahao Indonesia project approved; Jiafu overseas OEM |
Share Price & Returns
| Reference point | Price (HKD) | Source |
|---|---|---|
8 Dec 2021 (pre-placing close) | 20.30 | FY2021 announcement |
Dec 2021 placing price | 17.88 | FY2021 announcement |
Feb 2026 buyback range | 4.42–4.70 | 1H2026 announcement |
2 Feb 2026 (after a more than 10% fall) | 4.58 | etnet |
25 Mar 2026 (after a more than 10% rise) | 4.53 | etnet |
Apr 2026 (etnet quote) | 4.60 | etnet |
May–Jun 2026 buyback range | 3.18–3.88 | 1H2026 announcement |
31 Jul 2026 | 3.30 | etnet |
26 Aug 2026 | 3.255 | etnet |
Per-Share Data and Share Count (millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (HK cents) | 8.40 | 8.48 | 8.50 | 8.50 | 9.90 |
Weighted average shares (millions) | 3,111.9 | 3,229.9 | 3,229.9 | 3,229.9 | 3,229.9 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E (TTM, attributable) | Not meaningful (loss) | TTM attributable NI about −RMB403m |
P/E (TTM, Non-HKFRS profit incl. NCI) | About 46x | TTM Non-HKFRS profit about RMB199m |
P/B | About 0.81x | Attributable equity RMB11,293m |
EV | About RMB5.0bn | Market cap + NCI − net cash (incl. WMP) |
EV / Sales (TTM) | About 1.3x | TTM revenue RMB3,742m |
EV / adjusted EBITDA (TTM) | About 8.1x | TTM Non-HKFRS EBITDA RMB621m |
Dividend yield (FY2025 DPS) | About 3.0% | HK9.9c ÷ HK$3.255 |
Analyst Conclusions
Management guidance. There is no numeric guidance. The 1H2026 outlook commits to allocating resources to internationalisation, the health industry, innovative tobacco and high-potential customers. It also commits to accelerating Indonesian ramp-up and overseas plants, deepening joint R&D with global tobacco majors, building health-ingredient ODM capability and internationalising condiments. Management says 1H2026 laid a "solid foundation" for full-year targets, which are not quantified.
Consensus growth expectations. Not publicly verified.
Bull case
-
Growth inflection with operating leverage. 1H2026 revenue rose 15.9%, adjusted operating profit rose 19.2%, and administrative and selling expense ratios fell by 3.8 and 1.5 points respectively. If this continues, FY2026 adjusted operating profit could recover towards the FY2024 level of RMB292m or above.
-
Deep value with downside protection. The shares trade at about 0.8x book. Net cash including WMP of about RMB5.7bn is roughly 63% of market capitalisation, and EV/adjusted EBITDA is about 8x. A HK$500m buyback and a yield of about 3% support the shares.
-
Innovative tobacco optionality. A qualified Indonesian HNB-RTL base, supply-chain entry with the top three global tobacco companies, nicotine-pouch boba and possible Chinese national HNB standards could restore a high-margin growth engine. A collected RMB450.6m arbitration award would be a further one-off upside.
Bear case
-
Structural margin decline. Gross margin has fallen every year from 63.4% (FY2020) to 40.8%, and it did not improve in 1H2026. The high-margin domestic tobacco profit pool is shrinking permanently.
-
Capital allocation record. About RMB3.5bn of goodwill impairments and the failed Shanghai Yifang guarantees undermine confidence in the "organic plus M&A" strategy. RMB3.1bn of intangibles remains, much of it in the Jiahao CGU, where growth assumptions were cut again.
-
Governance and earnings quality. The family controls about 71%. The 2022–23 investigations, persistent share-based compensation (about RMB88m in 1H2026), reliance on finance income and grants, and RMB1.35bn of idle IPO proceeds all warrant a discount.
Key catalysts and monitorables (next 12 months)
-
FY2026 results (around Mar 2027), including any further Jiahao impairment test outcome
-
Indonesian RTL master supply agreement renewal and new international customer conversions
-
Recovery of Middle East tobacco customer demand
-
Finalisation of China's heated-cigarette and nicotine-pouch national standards
-
Enforcement and collection of the Shanghai Yifang award
-
Pace of buyback execution against the HK$500m authorisation
-
Start-up of the Indonesian food complex (2H2026) and the Paraguay capsule plant
-
Health base ramp-up (Shandong, Jiangxi) and the New Zealand decision
-
Gross margin trajectory, and whether it stabilises above 40%
-
Deployment of the RMB889.6m special account of unallocated IPO proceeds
Concluding analyst verdict
Huabao International is a cash-rich company in the middle of an uncomfortable transformation. For a decade it earned unusually high returns as a supplier to China's tobacco monopoly. That franchise is fading. Group gross margin has fallen more than 22 points since FY2020, F&F revenue has dropped by a third, and the tobacco-legacy CGUs have been repeatedly written down. Management's response has been to buy growth in condiments, ingredients and fragrances. The results have been poor. Roughly RMB3.5bn of goodwill has been written off in six years, and the Shanghai Yifang deal ended in arbitration.
The 1H2026 results are the first credible sign that the redesigned portfolio can grow. Revenue rose 15.9%, adjusted operating profit rose 19%, and cost ratios fell in a measurable way. Strategically, the most valuable asset may be the least visible: a qualified, overseas HNB-RTL and capsule platform supplying the world's largest tobacco companies, backed by an active patent programme. If China opens its domestic HNB market under the new national standards, Huabao is one of the few local suppliers with both domestic relationships and international qualifications.
Valuation already discounts much of the pessimism. The shares trade at about 0.8x book and about 8x adjusted EV/EBITDA, with net cash plus WMP equal to roughly two-thirds of market capitalisation, and the company is paying special dividends and buying back stock. The discount also reflects real problems: weak capital allocation, a family-controlled board with a recent history of investigations, low reported ROE and margins that are still falling.
Verdict: a value-with-optionality situation rather than a quality compounder. We would treat the stock as a balance-sheet-protected recovery candidate. Upgrading conviction would require three things: gross margin stabilising at or above 40%, a full year without impairments, and visible growth in international tobacco revenue. Failure on any of these would point to a continuing value trap.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / notes | Prior roles / background |
|---|---|---|---|
Ms. CHU Lam Yiu (朱林瑤) | Chairlady, Executive Director, Chair of Nomination Committee | Founder-controller. CEO from 9 Apr 2013 to 7 Jan 2026. Ultimate interest about 71% (Mar 2024). | Under PRC residential surveillance Jan 2022–Jul 2023; freed of all bail conditions 14 Jul 2023 |
Mr. XIA Liqun (夏利群) | CEO (from 7 Jan 2026), Vice Chairman, President, Executive Director, Remuneration Committee member | Long-standing Vice Chairman and President | — |
Mr. LAM Ka Yu (林嘉宇) | Co-Chairman, Vice President, Executive Director | Son of Ms. Chu; director of Huabao Technology | Subject to the same 2022 investigation; bail conditions removed Jul 2023 |
Mr. POON Chiu Kwok (潘昭國) | Vice President, Company Secretary, Executive Director | Signs most HKEX announcements | — |
Ms. LAM Ka Yan (林嘉炘) | Executive Director | Daughter of Ms. Chu | — |
Ms. CHOY Man Har (蔡文霞) | Executive Director; Deputy CFO (per 2023 disclosure) | — | Arrested by ICAC on 5 Jul 2023, released on bail without charge |
Mr. LEE Luk Shiu (李祿兆) | INED; Chair of Audit Committee | — | — |
Mr. Jonathan Jun YAN | INED; Audit Committee | — | — |
Mr. HOU Haitao (侯海濤) | INED; Audit Committee | Joined after FY2021; replaced Ms. MA Yunyan | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Jan 2022 – Jul 2023 | Chair/CEO and Co-Chairman under PRC investigation; duties shared by the Co-Chairman, Vice Chairman and President, and the Company Secretary | FY2023 announcement |
Jul 2023 | ICAC arrest of ED Choy Man Har (released without charge) | FY2023 announcement |
~2022–2023 | INED Ma Yunyan replaced by Hou Haitao | Board lists FY2021 vs FY2023 |
7 Jan 2026 | Xia Liqun appointed CEO; Chu Lam Yiu remains Chairlady | FY2025 announcement |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing | Approx. scale | Relative positioning |
|---|---|---|---|---|
Flavours & fragrances | Givaudan | SIX: GIVN | About CHF7bn revenue | Global leader; far larger, broader, higher R&D spend |
Flavours & fragrances | dsm-firmenich | Euronext: DSFIR | About EUR12–13bn | Global leader in taste, texture and health |
Flavours & fragrances | IFF | NYSE: IFF | About USD11bn | Global leader; strong China presence |
Flavours & fragrances | Symrise | XETRA: SY1 | About EUR5bn | Global; strong in pet food and aroma molecules |
Flavours & fragrances | Takasago | TSE: 4914 | About JPY200bn | Asian F&F major |
Flavours & fragrances | Sensient Technologies | NYSE: SXT | About USD1.5bn | Colours and flavours |
Flavours & fragrances (China) | Shanghai Apple Flavor & Fragrance | SSE: 603020 | — | Domestic F&F competitor |
Tobacco flavours / materials (China) | China Boton Group | HKEX: 3318 | — | Direct competitor in tobacco flavours and HNB |
Tobacco materials / HNB | Shenzhen Jinjia Group | SZSE: 002191 | — | Tobacco packaging and HNB materials |
Aroma chemicals (maltol etc.) | Anhui Jinhe Industrial | SZSE: 002597 | — | Leading maltol producer; price competition |
Condiments (chicken bouillon) | Totole (Nestlé), Knorr (Unilever) | — | Large MNC brands | Brand leaders in chicken essence and bouillon for catering |
Condiments (broad) | Foshan Haitian | SSE: 603288 / HKEX | Largest Chinese condiment maker | Scale leader; soy sauce focus |
Compound condiments | Yihai International, Baoli/others | HKEX: 1579 | — | Hot-pot and compound seasonings |
Peer Comparison FY2025
| Metric | Huabao (FY2025) | Givaudan (FY2024, approx.) | Symrise (FY2024, approx.) | IFF (FY2024, approx.) |
|---|---|---|---|---|
Revenue | RMB3.48bn (about USD0.48bn) | About CHF7.4bn | About EUR5.0bn | About USD11.5bn |
Revenue growth | +3.3% | — | — | — |
Gross margin | 40.8% | — | — | — |
Adjusted EBITDA margin | 16.5% | — | — | — |
R&D % of revenue | 8.2% | — | — | — |



